logo
Movement practice helps Parkinson's patients in Brazil ease symptoms

Movement practice helps Parkinson's patients in Brazil ease symptoms

Euronews16-07-2025
Nilma Teles de Freitas, an 80-year-old retired teacher in Brazil who was diagnosed with Parkinson's disease more than a decade ago, says she used to fall over all the time.
That changed after she began attending a capoeira class in downtown Rio de Janeiro especially designed for people with the neurodegenerative illness.
Capoeira is a movement practice that originated within the large enslaved communities in Brazil, where nearly five million kidnapped Africans disembarked during the transatlantic slave trade that started in the 16th century.
It is considered both a martial art and a dance, combining ritual, exercise, spirituality, and music.
'Capoeira gives me freedom to work on my body. What I can do. What I can't do. So I can have balance and a more comfortable life,' Teles de Freitas said during a recent class.
Regaining balance
Practiced for centuries by Afro-Brazilians, it has since become popular around the world. UNESCO recognized the practice in 2014 as Intangible Cultural Heritage.
The project started in 2018 with physical therapist Rosimeire Peixoto, 60, who at that point had been attending capoeira classes herself for over a decade.
After working with many patients with Parkinson's, she said she became convinced that introducing them to capoeira may help alleviate some of their symptoms.
Parkinson's has a range of different symptoms, and along with difficulties in balancing, some common ones include slowness of movement, tremors, and stooped posture. Patients can also experience anxiety, depression, sleeping disorders, and nausea.
'I had the idea after reading an article that said alternating both hands when using a cell phone stimulates both hemispheres of the brain,' she said.
'And as a physiotherapist treating neurological patients, I was lacking exercises that would motivate them'.
Peixoto's project was dubbed "Parkinson na ginga' – or 'Parkinson's in the swing' – a reference to the first fluid, rhythmic step that capoeira practitioners learn. She now holds classes twice a week in the Progress Foundry, a sprawling cultural center in downtown Rio next to a famed white 18th century aqueduct and surrounded by palm trees.
Capoeira helps improve balance, coordination, and strength, with music loosening up tense bodies, Peixoto says.
'There is a lot happening in a capoeira circle. They feel the vibration, the energy, they pay attention to the music and to the partner to dodge blows' and to themselves, she said.
Bridging health and community
During a recent class, Peixoto walked among the students, placing a gentle hand on a back here and there to help with balance, patiently repeating demonstrations and offering words of encouragement.
Antônio de Azevedo, who was diagnosed with Parkinson's disease a few years ago, said he could hardly stand before. But since he started practicing capoeira, his stability returned.
'It's the best thing that's ever happened to me,' he said while he attended a capoeira class with around 10 other people, all with Parkinson's.
Peixoto tries to make the classes a fun and social event – she often suggests a group samba dance at the end of the class, and regularly brings a cake to share.
Teles de Freitas, the retired teacher, says that she loves the camaraderie among the class.
'We are there for one another,' she said. 'Feeling and conversing with friends gives strength'.
She remembers how when she got her diagnosis, she left the doctor's office crying, terrified of the future.
'Today I'm smiling," she said. "I'm managing to live. I'm managing to interact with other people. I'm managing to be happy'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Light stimulation shows promise in slowing Parkinson's, scientists say
Light stimulation shows promise in slowing Parkinson's, scientists say

Euronews

timea day ago

  • Euronews

Light stimulation shows promise in slowing Parkinson's, scientists say

French scientists are experimenting with a new way to combat Parkinson's disease: using light to stimulate damaged nerve cells in the brain. Researchers from a biomedical research centre affiliated with Grenoble University Hospital announced their progress on Radio France, explaining that while the trial is still at a very early stage, it could lead to breakthroughs in the treatment of the neurodegenerative disease. Around 10 million people worldwide have Parkinson's, and that figure is expected to double by 2050, according to Parkinson's Europe. There is no cure, but researchers have been searching for ways to slow the disease and alleviate symptoms, which include tremours, muscle rigidity, and slowness of movement. If it is successful in larger studies, the French clinical trial could help disrupt the progression of the disease through a non-invasive technique that stimulates the functional recovery of neurons, or nerve cells. The study targets dopamine-secreting neurons, which are critically affected as Parkinson's progresses. Around half of these cells may be damaged by the time symptoms appear, while patients lose an average of 10 per cent of their dopamine receptors per year, according to Dr Stephan Chabardès, a neurosurgeon at Grenoble University Hospital. The aim of the trial is to slow down patients' neurological deterioration, Chabardès said. The technique directs light beams to neurons deep inside the brain to target mitochondria – responsible for energy production within the cell – to stimulate them and improve their function, thereby revitalising the damaged cells. Chabardès said that in order to access these deep brain regions, the researchers developed a special compact device that combines advanced expertise in electronics, photonics, and nanotechnology, enabling the system to get smaller without sacrificing performance. "It is the combination of this medical expertise in neurosurgery with expertise in micro and nanotechnologies that makes it possible to achieve these medical feats," he said. So far, the technology has been applied to seven patients with early stages of the disease, and preliminary results indicate a slowdown in the deterioration of symptoms in three of them, especially with continued stimulation. It appeared that the light stimulation helped restore some brain function in these three cases, Chabardès said. "It's very preliminary, but what we are seeing is quite promising," Chabardès said. He noted that researchers will only launch a larger clinical trial if the study finds a tangible and stable effect.

Pharma giant Roche sees income soar in first half
Pharma giant Roche sees income soar in first half

France 24

time24-07-2025

  • France 24

Pharma giant Roche sees income soar in first half

It also reported that four potentially "practice-changing" drugs -- to treat Alzheimer's, Parkinson's, haemophilia and an antibiotic to fight a drug-resistant bacteria strain -- had advanced to the final stage of clinical development. Net income jumped 17 percent to reach 7.8 billion Swiss francs ($9.85 billion), while the Basel-based group confirmed its full-year outlook. Its sales exceeded forecasts, rising four percent to 30.9 billion Swiss francs -- or a seven-percent hike excluding currency effects, the world leader in cancer treatments said in a statement. Roche has two branches: pharmaceuticals and diagnostics. Its pharmaceuticals division saw sales rise 10 percent, at constant exchange rates, to 24 billion francs, primarily thanks to five "growth driver" medicines, including for breast cancer and asthma, which achieved total sales of 10.6 billion francs. That was 1.7 billion more than during the first half of 2024. Sales in its diagnostics division, however, were flat at constant exchange rates, at 6.95 billion francs. "We received numerous important approvals and reported positive data in disease areas with high unmet medical need," said Roche chief executive Thomas Schinecker. "Over the past six months, we have made significant progress in our pipeline and advanced four potentially practice-changing therapies into the final phase of clinical development," he said. These are NXT007 in haemophilia A, trontinemab in Alzheimer's disease, prasinezumab in early-stage Parkinson's disease, and zosurabalpin, "a novel antibiotic that could become the first in over 50 years to tackle a type of bacteria that has become resistant to most other treatments". For the full year, Roche said it was still targeting mid-single-digit sales growth excluding currency effects, equivalent to around five percent growth. In April, Roche announced plans to invest $50 billion in the United States over the next five years, following in the footsteps of Swiss rival Novartis, with US President Donald Trump's tariff war fuelling uncertainty in the sector. The United States is a key market for the pharmaceutical industry, representing around half of sales in Roche's pharmaceutical division.

What to know about Parkinson's disease after Ozzy Osbourne's death
What to know about Parkinson's disease after Ozzy Osbourne's death

Euronews

time24-07-2025

  • Euronews

What to know about Parkinson's disease after Ozzy Osbourne's death

Heavy metal rocker Ozzy Osbourne died this week aged 76, just weeks after his farewell show and about five years after announcing he had Parkinson's disease. Here's what to know about the disease. What is Parkinson's? Parkinson's is a neurologic disease that robs people of control over their movements. It typically starts with tremors and is characterised by slow movement, a shuffling gait, stiff limbs, balance problems, and slurred speech. Who gets it? About 10 million people are living with Parkinson's worldwide, according to the Parkinson's Foundation. It usually appears after age 60, although sometimes it can develop before age 50. What causes Parkinson's? The exact cause isn't known, but Parkinson's develops when cells that produce one of the brain's chemical messengers, called dopamine, begin to deteriorate and die. Dopamine transports signals to parts of the brain that control movement. Parkinson's symptoms appear after enough dopamine-producing cells die that there's too little of this neurotransmitter in the brain. According to the foundation, most experts believe genetic and environmental factors are behind the disease. Dozens of gene mutations linked to Parkinson's have been discovered, and genetics account for 10 per cent to 15 per cent of all cases. Other factors suspected of increasing the risk include head injuries, exposure to pesticides and herbicides, and where you live. Is there a cure? There is no cure but there are treatments, including medications that affect dopamine levels and a surgically implanted tremor-blocking device. Patients also can benefit from physical and occupational therapy. What's the prognosis? Symptoms worsen over time, usually slowly. The severity of symptoms and how quickly they progress vary widely between patients. In advanced cases, people may be unable to walk or care for themselves. They also can suffer from depression as well as memory and thinking problems. While Parkinson's itself isn't considered fatal, people can die from complications of the disease, including lung problems as muscle weakness impedes the ability to cough and to swallow.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store